首页 | 本学科首页   官方微博 | 高级检索  
检索        

不同评分系统对慢性阻塞性肺疾病急性加重患者28天生存率的预测价值
引用本文:叶世华.不同评分系统对慢性阻塞性肺疾病急性加重患者28天生存率的预测价值[J].内科急危重症杂志,2019,25(5):364-366.
作者姓名:叶世华
作者单位:华中科技大学同济医学院附属同济医院
基金项目:基金项目:国家自然基金科学基金(No:81300410、81873444)
摘    要:目的:探讨不同评分系统对慢性阻塞性肺疾病急性加重期(AECOPD)患者28 d生存率的预测价值。方法:收集AECOPD患者150例,均进行积极常规救治,采用BAP-65评分、急性生理与慢性健康状况评分Ⅱ(APACHEⅡ)及慢性阻塞性肺疾病和支气管哮喘生理评分(CAPS)对28 d生存率进行预测。根据预后将患者分为死亡组12例和存活组138例。结果:死亡组患者APACHEⅡ评分与CAPS评分均明显高于存活组(P0.05),两组BAP-65评分差异有统计学意义(P0.05)。3种评分系统中APACHEⅡ评分对AECOPD患者28 d生存率预测曲线下面积最大,为0.917,且其敏感性及特异性均最大,分别为89.06%及83.88%,CAPS评分与BAP-65评分曲线下面积分别为0.828、0.888,且诊断敏感性及特异性均在70%以上。结论:BAP-65评分、APACHEⅡ评分及CAPS评分对AECOPD患者28 d生存率均有较高的预测价值,且APACHEⅡ评分预测价值最佳。

关 键 词:抗PD-1抗体  不良反应
收稿时间:2019/9/1 0:00:00
修稿时间:2019/9/17 0:00:00

Predictive value of different scoring systems for 28-day survival rate in patients with acute exacerbation of chronic obstructive pulmonary disease
JIANG Li-jun,XU Bin,GAO Li-li,ZHAO Lei,Xiao Yi,Wang Di and ZHOU Jian-feng.Predictive value of different scoring systems for 28-day survival rate in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Journal of Internal Intensive Medicine,2019,25(5):364-366.
Authors:JIANG Li-jun  XU Bin  GAO Li-li  ZHAO Lei  Xiao Yi  Wang Di and ZHOU Jian-feng
Institution:Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract:Objective: To investigate the value of different scoring systems in predicting 28-day survival rate in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 150 AECOPD patients were enrolled. All patients underwent routine treatment with a BAP-65 score, APACHE II score, and CAPS score to predict 28-day survival. Patients were divided into death group (12 cases) and survival group (138 cases) according to the prognosis of patients. Results: The APACHE II score and CAPS score in the death group were significantly higher than those in the survival group (P<0.05). The difference in BAP-65 scores between the two groups was statistically significant (P<0.05). The ROC results showed that the APACHE II score in the three scoring systems had the largest area under the 28-day survival rate prediction curve for AECOPD patients, and the sensitivity and specificity were 89.06% and 83.88%, respectively. The CAPS score and BAP-65 score curves were obtained. The lower area was 0.828 and 0.888, respectively, and the diagnostic sensitivity and specificity were above 70%. Conclusion: The BAP-65 score, APACHE II score and CAPS score have a higher predictive value for 28-day survival rate in patients with AECOPD, and the predictive value of the APACHE II score is the highest.
Keywords:anti-PD-1 antibody  adverse effects
本文献已被 CNKI 等数据库收录!
点击此处可从《内科急危重症杂志》浏览原始摘要信息
点击此处可从《内科急危重症杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号